INTRODUCTION

Attention-deficit/hyperactivity disorder (ADHD) is the most common childhood disorder in psychiatric outpatient clinics and affects 3%-8% of the pediatric population worldwide (1). On contrary to previous notion as a condition of childhood, it has been known that ADHD continues and causes significant psychosocial impairment across life span (2). It has been reported that children and adolescents with ADHD have increased risks for challenging behaviors, school drop-out, earlier substance use associated with conduct problem, and problem gambling, as well as mood and anxiety disorders (3-6). Adults with ADHD had high risk for a wide range of adverse psychosocial outcomes including low academic achievement, low socioeconomic status, low rates of professional employment, and difficulty in maintaining occupational status and social relationships as well as increased rates of psychopathology including antisocial, addictive, mood and anxiety disorders (7).

Considering the chronic nature and adverse outcome of ADHD, earlier detection...
and better adherence to treatment seem to be important throughout treatment period. Along with behavioral treatment and educational intervention, medication leads to not only the reduction of core symptoms but also the improvement of academic difficulties, behaviors problems, and psychiatric comorbidities in children and adolescents with ADHD (8-10). Stimulants were considered as the first-line therapy for children with ADHD. While shorter half-life of immediate-release methylphenidate hindered children and adolescents with ADHD from adhering to their medication, the extended-release or osmotic-controlled release oral delivery system methylphenidate improved adherence and efficacy (11,12). In addition, nonstimulants including atomoxetine have been used alternatively for the treatment of ADHD in children and adolescents (13). However, suboptimal treatment and poor medication compliance were not uncommon even for 12 months of treatment (14,15).

In the current study, we categorized the data of children and adolescents with the ADHD into 4 groups as follows: 1) immediate-release methylphenidate (IR-MPH), 2) extended-release methylphenidate (ER-MPH), 3) osmotic-controlled release oral delivery system methylphenidate (OROS-MPH), and 4) atomoxetine (ATX). If different medications were used in their initial 2 visits in 2010, the medication prescribed more frequently and/or at a higher dosage in the first 2 visits was selected as an initial one. In addition, the change of initial drug was regarded as a discontinuation. In 2010, clonidine was withdrawn from market and not available in Korea. Atomoxetine was only covered from the Korean NHI system when specific comorbid conditions, such as a severe anxiety and Tourette syndrome, were present in children and adolescents with ADHD. The combination of these medications was typically not covered by Korean National Insurance. Data of the subjects were followed up from the initiation of treatment with ADHD medications in 2010 (index event) to December 31, 2013.

In the current study, persistence was defined as the number of days of continuous treatment with medication during the post-index period (from the index date to the last date of medication prescription). Considering frequent drug holiday during either vacation or weekend in the treatment of children and adolescents with ADHD, we defined the refill gap longer than 60 days (GAP60) as well as the conventional 30 days or more refill gap (GAP30) as discontinuation of a treatment. In addition, for sensitivity analysis, 15 days or more refill gap was used in order to check the robustness of the results. Adherence was calculated using the Medication Possession Ratio (MPR) which reflects the proportion of days that patients were in possession of their prescribed medication. In the current study, the MPR was calculated by summing days being supplied and dividing by days being treated (i.e., the day intervals between the last date of medication prescription and index date). We evaluated the adherence using the MPR with the conventional 70% and 80% cut-offs. Sensitivity analysis was also conducted at 90% cut-off. Utilization parameters during post-index period including persis-
tence and adherence were measured for 36 months or more.

Along with sex, children and adolescents with ADHD were divided into 2 age groups as follows: 6-12 and 13-18 years of age. The insurance type was classified into two categories: National Health Insurance and Medical Aid. The hospital level was stratified into two groups: general hospitals and private clinics.

**Statistical analysis**

Differences among ADHD medications in the number of those who discontinued and remained adherence were analyzed using χ² test. Mean days before discontinuation were compared using ANOVA with post-hoc comparison. To assess the association between medications and persistence and adherence, a multivariate logistic regression analysis was employed, controlling for age, sex, and hospital level. SAS 9.3 (SAS Institute, Inc., Cary, NC, USA) was used to analyze the data. An a priori significance level of P < 0.05 was used throughout all statistical analyses.

**Ethics statement**

The current study was approved by the institutional review board of Eulji University, Eulji General Hospital, Seoul, Korea (IRB No. 2015-01-012). Informed consent was exempted by the board.

### Table 1. Characteristics of 10,343 eligible children and adolescents in the current study

| Demographic parameters                  | No. (%) of subjects |
|----------------------------------------|---------------------|
| **Age group**                           |                     |
| Children (6-12 years of age)            | 7,592 (73.4)        |
| Adolescents (13-18 years of age)        | 2,751 (26.6)        |
| **Sex**                                 |                     |
| Boys                                    | 8,223 (79.5)        |
| Girls                                   | 2,120 (20.5)        |
| **Insurance type**                      |                     |
| Korean national health insurance        | 10,272 (99.3)       |
| Korean medical care                     | 71 (0.7)            |
| **Hospital level**                      |                     |
| General hospitals                       | 2,961 (27.8)        |
| Private clinics                         | 7,382 (72.4)        |

ADHD, attention-deficit/hyperactivity disorder; IR-MPH, immediate-release methylphenidate; OROS-MPH, osmotic-controlled release oral delivery system methylphenidate; ATX, atomoxetine.

### Table 2. Persistence of ADHD medications

| Medications      | Frequency, No. (%) | Duration of persistence before GAP30 (Mean ± SD) | Discontinuation using GAP30, No. (%) | Duration of persistence before GAP60 (Mean ± SD) | Discontinuation using GAP60, No. (%) |
|------------------|--------------------|-----------------------------------------------|------------------------------------|-----------------------------------------------|--------------------------------------|
| IR-MPH           | 684 (6.6)          | 181.1 ± 225.0                                   | 668 (97.7)                         | 367.0 ± 274.1                                 | 388 (56.7)                          |
| ER-MPH           | 2,323 (22.5)       | 187.2 ± 221.1                                   | 2,297 (98.9)                      | 403.1 ± 291.2                                 | 1,448 (62.3)                        |
| OROS-MPH         | 5,739 (55.5)       | 175.2 ± 202.1                                   | 5,691 (99.3)                      | 394.0 ± 292.1                                 | 3,510 (61.2)                        |
| ATX              | 1,597 (15.4)       | 192.3 ± 227.3                                   | 1,588 (99.4)                      | 405.2 ± 274.0                                 | 986 (61.7)                          |
| F or χ²          |                    | F = 3.604                                       | χ² = 17.917                       | F = 3.418                                      | χ² = 7.224                          |
| P value          |                    | 0.013                                            | 0.001                             | 0.017                                          | 0.065                               |
| Post hoc Tukey test |                | a < c < b                                      | a < c < b                        | a < c < b                                      | -                                   |

ADHD, attention-deficit/hyperactivity disorder; GAP30, 30 days refill gap; GAP60, 60 days refill gap; IR-MPH, immediate-release methylphenidate; ER-MPH, extended-release methylphenidate; OROS-MPH, osmotic-controlled release oral delivery system methylphenidate; ATX, atomoxetine.

### Table 3. Adherence of ADHD medications

| Medications      | Frequency, No. (%) | Adherent, MPR ≥ 80, No. (%) | Adherent, MPR > 70, No. (%) |
|------------------|--------------------|-------------------------------|-------------------------------|
| IR-MPH           | 684 (6.6)          | 188 (27.5)                    | 231 (33.8)                    |
| ER-MPH           | 2,323 (22.5)       | 709 (30.5)                    | 861 (37.1)                    |
| OROS-MPH         | 5,739 (55.5)       | 1,610 (28.1)                  | 1,989 (34.8)                  |
| ATX              | 1,597 (15.4)       | 349 (26.7)                    | 557 (33.6)                    |
| χ² value         |                    | 7.884                          | 6.455                         |
| P value          |                    | 0.017                          | 0.065                         |

ADHD, attention-deficit/hyperactivity disorder; MPR, medication possession ratio; IR-MPH, immediate-release methylphenidate; ER-MPH, extended-release methylphenidate; OROS-MPH, osmotic-controlled release oral delivery system methylphenidate; ATX, atomoxetine.

## RESULTS

In 2010 Korean HIRA claims database, the total number of newly diagnosed children and adolescents with ADHD was 28,436. Our study sample consisted of 10,343 children and adolescents with ADHD who were not given their newly prescribed medication in 360 days before the initial claim in 2010. They were largely 6-12 years of age (n = 7,592, 73.4%), boys (n = 8,223, 79.5%), those who had Korean National Health Insurance (n = 10,272, 99.3%), and those who were treated in private clinics (n = 7,382, 72.4%). The most frequently prescribed drug was OROS-MPH (n = 5,739, 55.5%), followed by ER-MPH (n = 2,323, 22.5%), ATX (n = 1,597, 15.4%), and IR-MPH (n = 684, 6.6%) (Table 1).

Comparisons of persistence and adherence among 4 ADHD medication groups are presented in Tables 2 and 3. Among 4 ADHD medication groups, significant difference was found in number of children and adolescents who had more than GAP30 (χ² = 17.917, P < 0.001) during their individual follow-up period. The lowest mean days before GAP30 were 175.2 ± 202.1 in OROS-MPH group, followed by 181.1 ± 225.0 in IR-MPH group, 187.2 ± 221.1 in ER-MPH group, and 192.3 ± 227.3 in ATX group (ANOVA: F = 3.604, P = 0.013, IR-MPH, OROS-MPH < ER-MPH, ATX in post hoc Tukey test). There were a trend toward significance when we used GAP60 (Chi-square test: χ² = 7.224, P = 0.065). The mean days before GAP60 was 367.0 ± 274.1 in IR-MPH group, 403.1 ± 291.2 in ER-MPH group, 394.0 ± 292.1 in OROS-MPH group, followed by 181.1 ± 225.0 in IR-MPH group, 192.3 ± 227.3 in ATX group, and 187.2 ± 221.1 in ER-MPH group.
group, 405.2 ± 274.0 in ATX group, respectively (F = 3.418, P = 0.017, IR-MPH < OROS-MPH < ER-MPH, ATX in post hoc Tukey test) (Table 2).

Using 80% cut-off of the MPR, 188 (27.5%) in IR-MPH group, 708 (30.5%) in ER-MPH group, 1,610 (28.1%) in OROS-MPH group, and 349 (26.7%) in ATX group achieved the adherence, which was significantly different (χ² = 7.884, P = 0.048). There was a trend of significance in the MPR using 70% cut-off (χ² = 6.455, P = 0.091) (Table 3).

Results from the multivariate logistic regression analyses of persistence (30 and 60 days refill gap), adherence (MPR 70% and 80%), and 4 ADHD medications controlling for age, sex, and the hospital level were presented in Tables 4 and 5. When we used GAP30, ER-MPH, OROS-MPH, and ATX groups showed less discontinuation compared to IR-MPH group [odds ratio (OR) = 0.528, 95% CI: 0.279-0.996, P = 0.049; OR = 0.360, 95% CI: 0.203-0.639, P < 0.001; OR = 0.270, 95% CI: 0.118-0.618, P = 0.002]. Using GAP60, multivariate logistic regression showed OROS-MPH group had a statistical tendency toward more persistent than IR-MPH (OR = 0.859, 95% CI: 0.731-1.011, P = 0.068). In addition, no significant differences were observed with other 2 ADHD medications compared to IR-MPH. Regarding covariates, general hospitals had a tendency toward more persistence compared to private clinics when we used GAP30 (OR = 0.597, 95% CI: 0.357-1.000, P = 0.050). In addition, when we used GAP60, children (6-12 years of age) discontinued less than adolescents (13-18 years of age) (OR = 0.693; 95% CI: 0.632-0.759, P < 0.001), while general hospitals were associated with less discontinuation compared to private clinics (OR = 0.526; 95% CI: 0.479-0.577, P < 0.001), respectively. In sensitivity analysis, results were similar those for GAP30 in the association between persistence and ADHD medications. However, sex was rather significant covariate than hospital level in that case (OR = 1.602, 95% CI: 1.021-2.513, P = 0.040) (Table 4).

Logistic regression analysis of adherence showed no differences among 4 medication types. Regarding covariates, girls were more adherent compared to boys (80% cut-off applied, OR = 1.165, 95% CI: 1.048-1.294, P = 0.005; 70% cut-off applied, OR = 1.198; 95% CI: 1.084-1.324, P < 0.001) and general hospitals were significantly more adherent than private clinics (80% cut-off applied, OR = 1.573; 95% CI: 1.434-1.725, P < 0.001; 70% cut-off applied, OR = 1.608; 95% CI: 1.472-1.757, P < 0.001), re-

| Variables | Likelihood of discontinuation (GAP30) | Likelihood of discontinuation (GAP60) |
|-----------|--------------------------------------|--------------------------------------|
| Medication types | Odds ratio | 95% CI | P | Odds ratio | 95% CI | P |
| ER-MPH | 0.528 | 0.279-0.996 | 0.049 | 0.886 | 0.743-1.056 | 0.175 |
| OROS-MPH | 0.360 | 0.203-0.639 | < 0.001 | 0.859 | 0.731-1.011 | 0.068 |
| ATX | 0.270 | 0.118-0.618 | 0.002 | 0.927 | 0.771-1.115 | 0.421 |
| Age group | |  |  |  |  |  |
| Children | 0.710 | 0.462-1.092 | 0.119 | 0.693 | 0.632-0.759 | < 0.001 |
| Girls | 1.444 | 0.927-2.251 | 0.104 | 1.061 | 0.961-1.171 | 0.245 |
| Hospital level | |  |  |  |  |  |
| General hospitals | 0.597 | 0.357-1.000 | 0.050 | 0.526 | 0.479-0.577 | < 0.001 |

ADHD, attention-deficit/hyperactivity disorder; GAP30, 30 days refill gap; GAP60, 60 days refill gap, IR-MPH, immediate-release methylphenidate; ER-MPH, extended-release methylphenidate; OROS-MPH, osmotic-controlled release oral delivery system methylphenidate; ATX, atomoxetine.

*Reference categories: IR-MPH, adolescents, boys, and private clinics.

Table 5. Logistic regression analysis of ADHD medication types and likelihood of discontinuation*

| Variables | Likelihood of discontinuation (MPR ≥ 80) | Likelihood of discontinuation (MPR ≥ 70) |
|-----------|--------------------------------------|--------------------------------------|
| Medication types | Odds ratio | 95% CI | P | Odds ratio | 95% CI | P |
| ER-MPH | 1.112 | 0.918-1.346 | 0.277 | 1.114 | 0.929-1.335 | 0.245 |
| OROS-MPH | 0.994 | 0.831-1.188 | 0.944 | 1.002 | 0.847-1.186 | 0.979 |
| ATX | 0.899 | 0.734-1.101 | 0.302 | 0.931 | 0.769-1.128 | 0.466 |
| Age group | |  |  |  |  |  |
| Children | 1.020 | 0.923-1.127 | 0.703 | 0.998 | 0.909-1.097 | 0.974 |
| Girls | 1.165 | 1.048-1.294 | 0.005 | 1.198 | 1.084-1.324 | < 0.001 |
| Hospital level | |  |  |  |  |  |
| General hospitals | 1.573 | 1.434-1.725 | < 0.001 | 1.608 | 1.472-1.757 | < 0.001 |

ADHD, attention-deficit/hyperactivity disorder; IR-MPH, immediate-release methylphenidate; ER-MPH, extended-release methylphenidate; OROS-MPH, osmotic-controlled release oral delivery system methylphenidate; ATX, atomoxetine.

*Reference categories: IR-MPH, adolescents, boys, and private clinics.
spectives. In sensitivity analyses using 90% cut-off, similar results were found for both 70% and 80% adherence cut-off level (Table 5).

DISCUSSION

The aim of the current study was to investigate differences in ADHD medication utilization patterns across a follow-up period. In the present study, we retrospectively explored the associations between 4 available medications in Korea and persistence and adherence in children and adolescents with ADHD. To our best of knowledge, this is the first study comparing both persistence and adherence among ADHD medications directly in children and adolescents in Korea. In addition, the follow-up period in the current study, at least 36 months, was the longest observation period for adherence in treatment of ADHD until now. In previous studies, most had observation period up to 1 year (22). Until the current study, the longest treatment duration was 6 years for treatment discontinuation and 2 years for adherence (23,24).

Discontinuation rates for 4 ADHD medications in our sample ranged from 97.7% for IR-MPH to 99.4% for ATX using GAP30 and from 56.7% for IR-MPH to 62.3% for ER-MPH using GAP60. In the number of discontinued, we found significant differences among medications using GAP30. Among 4 ADHD medications, ER-MPH and ATX had more days before both GAP30 and GAP60 than IR-MPH and OROS-MPH. In logistic regression analyses, ER-MPH, OROS-MPH, and ATX showed less discontinuation compared to IR-MPH group when GAP30 was used. Our results partially concurred with findings from previous studies, which suggested that there would be differences in ADHD medication discontinuation rates according to medication classes and action time in children and adolescents (15,17-20,25,26). The present results suggested that children and adolescents, who were treated by IR-MPH that has shorter action time and needs multiple daily doses, discontinued earlier and more than those treated by other 3 ADHD medications available in Korea.

In previous studies, the discontinuation rates within 1 year for stimulants ranged from 19.1% for long-acting stimulants in 15,838 subjects of all age in Quebec, Canada to 99% for short-acting MPH in 10,153 newly diagnosed children and adolescents with ADHD under 18 years of age in Taiwan (18,25). In addition, in Italian sample of children and adolescents, the discontinuation rate for ATX was 26.0% for 1 year (26). Similar to the current study, Barner et al. (15) enrolled 62,789 children and adolescents (3-18 years of age) in Texas Medicaid and compared differences in persistence using GAP30 among medication types including ATX. In their 1-year follow-up, ATX users persisted most, followed by ER-MPH, prodrug stimulant. In IR-MPH users, there was the lowest persistence. In the current study, we followed up data from the Korean HIRA claims database up to 3 years or more, which might explain partly higher discontinuation rate in our sample than previous results in other countries.

Although the effectiveness of ADHD medications has been demonstrated, treatment discontinuation is fairly common phenomenon. In previous studies, the discontinuation of ADHD medications has been associated with suboptimal control of symptoms, increasing the likelihood of harmful and serious behaviors including social adversity, academic difficulties, behavioral problems, and poor economic, social, and emotional well-being (28-30). In addition, family and associated community members can be influenced by these adverse consequences as well (31,32), which could not be measured in the current study because the data from the Korean HIRA claims database were not allowed to link with any information of their family members. In previous studies, changes in parenting stress and parental quality of life were measured during the 8-week treatment with OROS-MPH in children and adolescents with ADHD. Hwang et al. (31) found significant decreases in score of the Parenting Stress Index, Short Form from baseline to week 4 and from week 4 to 8, respectively in 495 parents whose children or adolescents with ADHD were treated. In addition, a significant improvement in parental World Health Organization Quality of Life, Brief Scale (WHOQOL-BREF) score was observed in 75 parents of children and adolescents with ADHD during treatment.

As was the case in persistence, there was a significant difference among medications in the number of those who were adherent when we used 80% cut-off of the MPR. The rate of subjects who had a MPR greater than 80% ranged from 26.7% for ATX to 30.5% for ER-MPH. In previous studies, it has been suggested that adherence to ADHD medications would be comparable with estimates for psychiatric disorders in adults including schizophrenia and bipolar disorder as well as chronic medical conditions with low adherence including hyperlipidemia, diabetes, hypertension, etc. (33-35). In previous studies using an 80% cut-off of the MPR, the rate of adherence for 12 months ranged from 8.3% for short-acting stimulants to 64% for long-acting stimulants including dexamphetamine, methylphenidate, and mixed amphetamine salts and 67% for nonstimulants (15,36). According to a recent meta-analysis (22), the pooled MPR in 12 months for children and adolescents ranged from 0.56 for long-acting stimulants to 0.67 for a nonstimulant (ATX). The rate of adherence in the current study was lower than those in previous studies. As the adherence levels can be changed due to study periods as well as medication classes and action time (22), results from previous studies should be interpreted cautiously.

In logistic regression analysis of adherence, we could not find any differences among 4 medication types in both 80% and 70% cut-off, which suggest that the adherence in long-term follow-up would be associated with other factors than medication. In logistic regression analyses of our samples, instead of medica-
tions, covariates including girls and general hospitals were associated with increased adherence. In addition, older age and private clinics would predict medication discontinuation. Recently, Charach and Fernandez (37) suggested that the adherence of ADHD medications could be decreased by several factors. Medication factors including medication ineffectiveness, adverse effects, multiple daily doses, and difficulties in adjusting the dose regimen could decrease the adherence. In addition, for the parent and family factors, older parents, increased parent-child conflict, bad belief or stigma (e.g., “ADHD symptoms are not a disorder”, “drugs are not safe”, “I cannot believe medical system”, and so on), and burden of the medication regimen were associated with decreased adherence. The Healthcare system and professional factors included the cost of medication and the lack of providers in the community. For the child factors, older age at diagnosis, family history of ADHD, severe behavior problems at home, and unwillingness were listed. At last, for the adolescent factors, negative attitudes toward medication, stigma, concerns about treatment dependence, and experience of social withdrawal seemed to decrease the adherence.

In the current study, while there was no difference in discontinuation between sex, girls with ADHD were more adherent than boys, as was contrary to the previous notion of low medication adherence in female sex (38). Generally, as comorbidities were associated with low medication adherence (38), we speculated that the result of higher adherence in girls with ADHD may result from differences in comorbidity pattern. Girls with ADHD tend to have lower self-efficacy and internalize their symptoms while they show less hyperactivity-impulsivity symptoms and externalizing behaviors including physical aggression which may cause an increase of parent-child conflict and severe behavior problems at home, and unwillingness toward medication (37,39).

The current study has several strengths. First, the use of HIRA data enabled us to evaluate the patterns of medication use in nearly entire population of children and adolescent in Korea. Second, we were able to assess persistence and adherence with data of 36 consecutive months or more according to the types of medications used to treat ADHD. Third, using the prescription claims data, we could analyze the utilization pattern of atomoxetine which has relatively limited data compared to stimulants.

However, the current study also has several limitations. First, although Korean NHI system covers almost all population, some individuals worry about their privacy and will pay all the cost without the coverage of national insurance. This phenomenon is common in psychiatric field in Korea, which may cause the omission of some data. Second, in Korea, atomoxetine was introduced in 2009 and had indications only when specific comorbid conditions, such as a severe anxiety and Tourette syndrome, were present in children and adolescents with ADHD. Therefore, it was possible for atomoxetine users to have distinct utilization pattern compare to stimulants users. Third, because the change of initial drug was regarded as a discontinuation, mainly used medication could be different from the initial one. Fourth, the Korean HIRA claims database of NHI system permits only 5-year data because of the administrative reasons. Therefore we could not report the utilization patterns beyond 36 months. Finally, the influences of other factors that have been known to be associated with the utilization of ADHD medication (e.g., ADHD symptom level, general adaptation, stigma, concerns, and family factors) could not be considered in the current study. It has been known that patients as well as and their family members have negative attitudes to psychiatry as they fear of being mentally ill because of a stigma (40). They concern about negative outcomes of the unwanted revelation of their medical record. Some patients may pay in full without making claims to HIRA. Patients also choose other treatment including cognitive behavioral therapy (CBT), play therapy, or learning therapy, rather than pharmacological treatment. In addition, because the diagnosis related group system has been applied in all psychiatric patients with Korean Medical Care, there was a possibility that detailed diagnostic information might be omitted in the Korean HIRA database.

Better understanding of the influences of ADHD medication on the utilization pattern may lead to effective clinical intervention strategies for children and adolescents with ADHD and their parents. The results of the current study may contribute to add some evidence for effective adjustment of health care resources. Among Korean NHI system, persistence and adherence varied depending on medication types, with IR-MPH having the lowest values. Overall adherence and persistence of ADHD medications in Korea are suboptimal. We suggest therapeutic strategy that should be assessed regularly in order to improve future outcomes in children and adolescents with ADHD.

DISCLOSURE

The authors have no potential conflicts of interest to disclose.

AUTHOR CONTRIBUTION

Study design: Bhang SY, Hwang JW, Kwack YS, Joung YS, Lee S, Kim B, Sohn SH, Chung US, Yang J, Hong M, Bahn GH, Choi HY, Oh IH, Lee YJ. Acquisition of data: Bhang SY, Hwang JW, Kwack YS, Joung YS, Lee S, Kim B, Sohn SH, Chung US, Yang J, Hong M, Bahn GH, Choi HY, Oh IH, Lee YJ. Statistical analysis and interpretation of data: Choi HY. Writing the draft: Bhang SY. Revision of manuscript: Bhang SY, Hwang JW, Hong M, Lee YJ. Approval of the final version: all authors.

http://dx.doi.org/10.3346/jkms.2016.31.8.1284
ORCID

Soo-Young Bhang http://orcid.org/0000-0001-5254-0314
Jun-Won Hwang http://orcid.org/0000-0001-5407-8514
Young-Sook Kwack http://orcid.org/0000-0002-6071-238X
Yoo Sook Joung http://orcid.org/0000-0002-9225-4643
Sooyoung Lee http://orcid.org/0000-0003-2473-2954
Bongseo Kim http://orcid.org/0000-0002-2534-6986
Seok Han Sohn http://orcid.org/0000-0001-6130-9317
Un Sun Chung http://orcid.org/0000-0003-3871-1425
Jaewon Yang http://orcid.org/0000-0001-5064-5948
Minha Hong http://orcid.org/0000-0003-4924-1107
Geon Ho Bahn http://orcid.org/0000-0002-3550-0422
Hyung Yun Choi http://orcid.org/0000-0002-6134-3504
In-Hwan Oh http://orcid.org/0000-0002-5450-9887
Yeon Jung Lee http://orcid.org/0000-0002-6524-0447

REFERENCES

1. Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2003; 2: 104-13.
2. Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, Benson BS, Bakshtin O, Kinlan J, McClellan J, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002; 41: 265-498.
3. Barkley RA, Fischer M, Smallish L, Fletcher K. Young adult outcome of hyperactive children: adaptive functioning in major life activities. J Am Acad Child Adolesc Psychiatry 2006; 45: 192-202.
4. Reimer B, Mehler B, D’Ambrosio LA, Fried R. The impact of distractions on young adult drivers with attention deficit hyperactivity disorder (ADHD). Accid Anal Prev 2010; 42: 842-51.
5. Gupta R, Nower L, Derevensky JL, Blaszczynski A, Faregh N, Tempchek C. Problem gambling in adolescents: an examination of the pathways model. J Gambl Stud 2013; 29: 575-88.
6. Biederman J, Ball SW, Monuteaux MC, Mick E, Spencer TJ, McCreary M, Cote M, Faraone SV. New insights into the comorbidity between ADHD and major depression in adolescent and young adult females. J Am Acad Child Adolesc Psychiatry 2008; 47: 426-34.
7. Biederman J, Faraone SV, Spencer TJ, Mick E, Monuteaux MC, Aleardi M. Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin Psychiatry 2006; 67: 524-40.
8. Barbareis WJ, Katusic SK, Colligan RC, Weaver AL, Jacobsen SJ. Modifiers of long-term school outcomes for children with attention-deficit/hyperactivity disorder: does treatment with stimulant medication make a difference? Results from a population-based study. J Dev Behav Pediatr 2007; 28: 274-87.
9. Biederman J, Monuteaux MC, Spencer T, Wilens TE, Faraone SV. Do stimulants protect against psychiatric disorders in youth with ADHD? A 10-year follow-up study. Pediatrics 2009; 124: 71-8.
10. Wilens TE, Adamson J, Monuteaux MC, Faraone SV, Schillinge M, Westenberg D, Biederman J. Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents. Arch Pediatr Adolesc Med 2008; 162: 916-21.
11. Faraone SV, Biederman J, Zimmerman B. An analysis of patient adherence to treatment during a 1-year, open-label study of OROS methylphenidate in children with ADHD. J Atten Disord 2007; 11: 157-66.
12. Gau SS, Chen SJ, Chou WJ, Cheng H, Tang CS, Chang HL, Tsang BE, Wu YY, Huang YE, Chou MC, et al. National survey of adherence, efficacy, and side effects of methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. J Clin Psychiatry 2008; 69: 131-40.
13. Brown RT, Amler RW, Freeman WS, Perrin JM, Stein MT, Feldman HM, Pierce K, Wolraich ML; American Academy of Pediatrics Committee on Quality Improvement; American Academy of Pediatrics Subcommittee on Attention-Deficit/Hyperactivity Disorder. Treatment of attention-deficit/hyperactivity disorder: overview of the evidence. Pediatrics 2005; 115: e749-57.
14. Hwang JW. Major lessons from the MTA in treatment of attention-deficit hyperactivity disorder. J Korean Acad Child Adolesc Psychiatry 2010; 21: 3-10.
15. Barner JC, Khosa S, Oladapo A. ADHD medication use, adherence, persistence and cost among Texas Medicaid children. Curr Med Res Opin 2011; 27 Suppl 2: 13-22.
16. Jensen PS, Kettle L, Roper MT, Sloan MT, Dulcan MK, Hoven C, Bird HR, Bauermeister J, Payne JD. Are stimulants overprescribed? Treatment of ADHD in four U.S. communities. J Am Acad Child Adolesc Psychiatry 1999; 38: 797-804.
17. Perwien A, Hall J, Swensen A, Swindle R. Stimulant treatment patterns and compliance in children and adults with newly treated attention-deficit/hyperactivity disorder. J Manag Care Pharm 2004; 10: 122-9.
18. Lachaine J, Beauchemin C, Susanne R, Hodgkin PS. Treatment patterns, adherence, and persistence in ADHD: a Canadian perspective. Postgrad Med 2012; 124: 139-48.
19. McCarthy S, Wilton L, Murray ML, Hodgkins P, Asherson P, Wong IC. Persistence of pharmacological treatment into adulthood, in UK primary care, for ADHD patients who started treatment in childhood or adolescence. BMC Psychiatry 2012; 12: 219.
20. Pottegård A, Bjerregaard BK, Glintborg D, Kortegaard LS, Hallas J, Moreno SI. The use of medication against attention deficit/hyperactivity disorder in Denmark: a drug use study from a patient perspective. Eur J Clin Pharmacol 2013; 69: 589-98.
21. Kim JS. The Operation of Nationwide Health Insurance and Its Implications. Seoul: Korea Development Institute School of Public Policy and Management, 2012.
22. Gajria K, Lu M, Sikirica V, Greven P, Zhong Y, Qin P, Xie J. Adherence, persistence, and side effects of methylphenidate in children with ADHD. J Atten Disord 2007; 11: 157-66.
23. Bokhari FA, Heiland F, Levine P, Ray GT. Risk factors for discontinuing stimulants and major depression in adolescent and young adult females. BMC Psychiatry 2008; 8: 134-58.
24. Saloner B, Fullerton C, McGuire T. The impact of long-acting medications on attention-deficit/hyperactivity disorder treatment disparities. J Child Adolesc Psychopharmacol 2013; 23: 401-9.
25. Chen CY, Yeh HH, Chen KH, Chang IS, Wu EC, Lin KM. Differential effects of predictors on methylphenidate initiation and discontinuation...
among young people with newly diagnosed attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol* 2011; 21: 265-73.

26. Didoni A, Sequi M, Panei P, Bonati M; Lombardy ADHD Registry Group. One-year prospective follow-up of pharmacological treatment in children with attention-deficit/hyperactivity disorder. *Eur J Clin Pharmacol* 2011; 67: 1061-7.

27. Pali SR, Kamble PS, Chen H, Aparasu RR. Persistence of stimulants in children and adolescents with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol* 2012; 22: 139-48.

28. Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M. Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status. *Arch Gen Psychiatry* 1993; 50: 565-76.

29. Shaw M, Hodgkins P, Caci H, Young S, Kable J, Woods AG, Arnold LE. A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment. *BMC Med* 2012; 10: 99.

30. Klein RG, Mannuzza S, Olazagasti MA, Roizen E, Hutchison JA, Lashua EC, Castellanos FX. Clinical and functional outcome of childhood attention-deficit/hyperactivity disorder 33 years later. *Arch Gen Psychiatry* 2012; 69: 1295-303.

31. Hwang JW, Kim B, Kim Y, Kim TH, Seo WS, Shin DW, Woo YJ, Yoo H, Lee JS, Lee JH, et al. Methylphenidate-osmotic-controlled release oral delivery system treatment reduces parenting stress in parents of children and adolescents with attention-deficit/hyperactivity disorder. *Hum Psychopharmacol* 2013; 28: 600-7.

32. Kim Y, Kim B, Chang JS, Kim BN, Cho SC, Hwang JW. Parental quality of life and depressive mood following methylphenidate treatment of children with attention-deficit hyperactivity disorder. *Psychiatry Clin Neurosci* 2014; 68: 506-14.

33. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. *Psychiatr Serv* 1998; 49: 196-201.

34. Chapman SC, Horne R. Medication nonadherence and psychiatry. *Curr Opin Psychiatry* 2013; 26: 446-52.

35. Dunbar-Jacob J, Mortimer-Stephens MK. Treatment adherence in chronic disease. *J Clin Epidemiol* 2001; 54 Suppl 1: S57-60.

36. Hodgkins P, Sasané R, Meijer WM. Pharmacologic treatment of attention-deficit/hyperactivity disorder in children: incidence, prevalence, and treatment patterns in the Netherlands. *Clin Ther* 2011; 33: 188-203.

37. Charach A, Fernandez R. Enhancing ADHD medication adherence: challenges and opportunities. *Curr Psychiatry Rep* 2013; 15: 371.

38. Rolnick SJ, Pawloski PA, Hedblom BD, Asche SE, Bruzek RJ. Patient characteristics associated with medication adherence. *Clin Med Res* 2013; 11: 54-65.

39. Rucklidge JJ. Gender differences in ADHD: implications for psychosocial treatments. *Expert Rev Neurother* 2008; 8: 643-55.

40. Park JE, Cho SJ, Lee JY, Sohn JH, Seong SJ, Suk HW, Cho MJ. Impact of stigma on use of mental health services by elderly Koreans. *Soc Psychiatry Psychiatr Epidemiol* 2015; 50: 757-66.